

# Vuokko Nummi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4853926/publications.pdf>

Version: 2024-02-01

10  
papers

69  
citations

1684188

5  
h-index

1588992

8  
g-index

10  
all docs

10  
docs citations

10  
times ranked

151  
citing authors

#	ARTICLE	IF	CITATIONS
1	Joint health and treatment modalities in Nordic patients with moderate haemophilia A and B â€” The MoHem study. <i>Haemophilia</i> , 2020, 26, 891-897.	2.1	23
2	Platelets compensate for poor thrombin generation in type 3 von Willebrand disease. <i>Platelets</i> , 2020, 31, 103-111.	2.3	10
3	Haemophilia early arthropathy detection with ultrasound and haemophilia joint health score in the moderate haemophilia (MoHem) study. <i>Haemophilia</i> , 2021, 27, e253-e259.	2.1	10
4	Comprehensive reâ€”evaluation of historical von Willebrand disease diagnosis in association with whole blood platelet aggregation and function. <i>International Journal of Laboratory Hematology</i> , 2018, 40, 304-311.	1.3	8
5	Monitoring onceâ€”weekly recombinant factor <scp>IX</scp> prophylaxis in hemophilia B with thrombin generation assay and factor <scp>IX</scp> activity. <i>International Journal of Laboratory Hematology</i> , 2017, 39, 359-368.	1.3	6
6	Treatment outcomes in persons with severe haemophilia B in the Nordic region: The Bâ€”NORD study. <i>Haemophilia</i> , 2021, 27, 366-374.	2.1	6
7	Weekly recombinant <scp>FIX</scp> prophylaxis for severe haemophilia B in normal clinical practice: data from <scp>UKHCDO</scp> and Finland. <i>Haemophilia</i> , 2017, 23, e240-e243.	2.1	3
8	Intravenous immunoglobulin treatment in a type 3 von Willebrand disease patient with alloantibodies and a lifeâ€”threatening gastrointestinal bleed. <i>Haemophilia</i> , 2019, 25, e291-e293.	2.1	1
9	Bleeding phenotype of patients with moderate haemophilia A and B assessed by thromboelastometry and thrombin generation. <i>Haemophilia</i> , 2021, 27, 793-801.	2.1	1
10	Factor IX antibodies and tolerance in hemophilia B in the Nordic countries â€” The impact of F9 variants and complications. <i>Thrombosis Research</i> , 2022, 217, 22-32.	1.7	1